Kyverna Therapeutics (KYTX) Treasury Shares (2023 - 2026)

Kyverna Therapeutics' Treasury Shares history runs 4 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Treasury Shares rose 169.18% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 169.18% YoY) and the FY2025 annual result came in at $1.2 million, up 115.37% from the prior year.
• Treasury Shares was $1.7 million for Q1 2026 at Kyverna Therapeutics, up from $1.2 million in the prior quarter.
• Across five years, Treasury Shares topped out at $114.6 million in Q3 2023 and bottomed at $544851.0 in Q3 2024.
• A 4-year average of $37.7 million and a median of $1.3 million in 2025 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2024 — Treasury Shares sank 99.52% — and 2026, when it surged 169.18%.
• Kyverna Therapeutics' Treasury Shares stood at $114.6 million in 2023, then slumped by 99.52% to $549001.0 in 2024, then surged by 115.37% to $1.2 million in 2025, then soared by 44.6% to $1.7 million in 2026.
• Business Quant data shows KYTX's Treasury Shares at $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.